Caroline Godfrey, PepGen CEO
December 9, 2020 10:34 AM ESTUpdated 10:56 AM
Financing

RA Cap­i­tal backs Ox­ford spin­out Pep­Gen with a $45M Se­ries A, seek­ing to treat Duchenne and oth­er sim­i­lar dis­eases

Max Gelman

Senior Editor

Less than two months af­ter Pe­ter Kolchin­sky and Raj Shah an­nounced a new $461 mil­lion fund, the part­ners at RA Cap­i­tal Man­age­ment ap­pear to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times